(CercleFinance.com) – Sandoz, the generics and biosimilars division of Novartis in the process of being spun off, says it has completed the acquisition of the worldwide trademark rights for the leading systemic antifungal agent Mycamine (Funguard in Japan) from Stellas.
“With this acquisition of echinocandin, one of the three main classes of antifungals, Sandoz significantly strengthens its global hospital offer and its leading anti-infective portfolio,” she underlines.
Astellas reported Mycamine sales of 14.2 billion yen ($105 million) for the fiscal year ending March 31, 2023, with a global patient base of more than two million for the product.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
